Pancreatic Cancer Research

ResearcherXinxiang Central HospitalNo recent work listed

Pengli Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4535-7332; OpenAlex author ID A5101661033. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2021: 2 papers · 2022: 2 papers

Papers 4

  1. Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. Co-author DOI 10.1007/s00210-022-02203-9↗
  2. Resveratrol Exerts Antitumor Effects on Pancreatic Cancer by Inhibiting Notch Signaling Induced by Chronic Stress Co-author DOI 10.21203/rs.3.rs-2305575/v1↗
  3. Thioredoxin-interacting protein is a favored target of miR-125b, promoting metastasis and progression of pancreatic cancer via the HIF1α pathway. Co-author DOI 10.1002/jbt.22782↗
  4. miR-125b enhances metastasis and progression of cancer via the TXNIP and HIF1α pathway in pancreatic cancer. Co-author DOI 10.3233/cbm-203112↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qi Gao · 2 shared papers, 2021 · strength 0.38
  2. Guotai Wang · 2 shared papers, 2022 · strength 0.33
  3. MA Qing-yong · 1 shared paper, 2022 · strength 0.17
  4. Wanxing Duan · 1 shared paper, 2022 · strength 0.17
  5. He Jiang · 1 shared paper, 2022 · strength 0.16
  6. Qingyong Ma · 1 shared paper, 2022 · strength 0.16
  7. Ying Xiao · 1 shared paper, 2022 · strength 0.16
  8. Jingtao Gu · 1 shared paper, 2022 · strength 0.16
  9. Zheng Wang · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.